Disclosure: Charles B. Nemeroff discloses consultations with Xhale, Takeda, SK Pharma, Clintara/Bracket, Lilly, Skyland Trail, Mitsubishi Tanabe Pharma Development America, Taisho Pharmaceutical Inc, and Sunovion; he is a stockholder in Opko, Antares, Xhale, Celgene, Seattle Genetics, and Abbvie; he serves on the scientific advisory boards of Riverbend, the American Foundation for Suicide Prevention (AFSP), the Brain and Behavior Research Foundation, Xhale, the Anxiety and Depression Association of America (ADAA), and Skyland Trail; he serves on the board of directors of AFSP, Gratitude America, and ADAA; he receives income in excess of $10,000 from Clintara/Bracket, American Psychiatric Publishing, and Xhale; he holds two patents, one for a method and devices for transdermal delivery of lithium (US 6,375,990B1) and the other for a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). The remaining author has no relevant financial relationships to disclose.